The present invention relates to compositions and methods for the regulated and controlled expression of proteins. Methods for inducing anti-cancer immune responses in a subject are also provided.

The present invention provides an isolated methyl degron peptide and a fusion protein comprising a methyl degron peptide. Also, the present invention provides screening methods for agents affecting protein lifespan and anti-cancer agents. Moreover, the present invention provides methods of controlling protein lifespan, regulating protein expression, and treating cancers by using a methyl degron peptide or a methyl degron gene.

A protein complex including at least two monoclonal antibodies is provided. By using the protein complex, a system for simultaneously targeting at least two antigens is effectively constructed.

The present invention relates to compositions and methods for the regulated and controlled expression of proteins. Methods for inducing anti-cancer immune responses in a subject are also provided.

The invention relates to a method of controlling the level of a polypeptide sequence comprising administering a polypeptide sequence fused to a ubiquitin targeting protein which comprises a minimal degron structural motif. In particular, the polypeptide sequence comprises a chimeric antigen receptor therefore the present invention is useful in methods of cell and gene therapy where the activity of the chimeric antigen receptor needs to be controlled.

Disclosed are therapeutic compositions and methods for inducing an immune response to herpes simplex virus type 2 (HSV-2). More particularly, the invention relates to a method for inducing an immune response in a subject by introducing and expressing an HSV gD2-encoding DNA vaccine.

The present invention provides a method for detection of an inflammatory reaction, which comprises using a transformant or transgenic non-human animal transfected with a vector comprising a promoter for a gene encoding an inflammatory cytokine, a gene encoding a reporter protein, a gene encoding the inflammatory cytokine, and a gene encoding a proteolytic signal sequence to thereby detect an inflammatory reaction induced upon inflammatory stimulation in the transformant or in the transgenic non-human animal.

The methods and compositions described herein relate, in part, to the generation of a synthetic degradation system in E. coli that provides tunable control of the protein level of targeted genes by using components of the Mesoplasma florum tmRNA system. Provided herein are degradation tag variants that permit independent control of both the initial level and inducible degradation rate of attached proteins.

The present disclosure relates to tagged chimeric effector molecules and receptor molecules thereof for genetically engineering a host cell, wherein the recombinant host cell can be identified, isolated, sorted, induced to proliferate, tracked or eliminated using the tag. An exemplary receptor molecule is a chimeric antigen receptors (CARs) having an extracellular domain comprising a binding domain for a target, a hinge region and a tag cassette, a hydrophobic portion as a transmembrane domain and, an intracellular part with an effector domain. An exemplary target is CD19, an exemplary tag is a Step-tag. T cells recombinantly modified for expression of such molecules may be used in adoptive immunotherapy.

A polynucleotide encoding a degradation signal peptide is disclosed. The polynucleotide may comprise a nucleotide sequence encoding a degradation signal peptide, wherein the degradation signal peptide has an amino acid sequence comprising a sequence that is at least 75% identical to a sequence corresponding to amino acid residues 84-98 of SEQ ID NO: 1 (AtIAA7), 66-80 of SEQ ID NO: 2 (AtIAA3), 84-98 of SEQ ID NO: 3 (AtIAA17), 78-92 of SEQ ID NO: 4 (AtIAA14), 55-69 of SEQ ID NO: 5 (AtIAA5), or 167-181 of SEQ ID NO: 6 (AtIAA8), or a degradation signal peptide functionally and/or structurally equivalent thereto.